Takeda's Iclusig, or ponatinib, in combination with chemotherapy received accelerated approval from the FDA for the treatment of adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. The approval was based on Phase 3 trial data that showed 30% of patients who received ponatinib plus chemotherapy achieved minimal residual disease-negative complete response compared with 12% of patients who were treated with imatinib and chemotherapy.